biotech Value proposition
Neocor is dedicated to pioneering transformative therapies in cardiac care
We are currently developing a novel gene therapy approach targeting ischemic and rare genetic cardiac diseases, and moving from lab preclinical trials to regulatory trials.
The Company was founded in October and has received strong traction since inception.
We will be looking to strengthen our human and financial ressources in the coming month in order to start the regulatory pre clinical trials.
gene therapy, biotechnology, rare disease, and cardiologyOriginal language
Neocor is dedicated to pioneering transformative therapies in cardiac care
We are currently developing a novel gene therapy approach targeting ischemic and rare genetic cardiac diseases, and moving from lab preclinical trials to regulatory trials.
The Company was founded in October and has received strong traction since inception.
We will be looking to strengthen our human and financial ressources in the coming month in order to start the regulatory pre clinical trials.
Neocor Therapeutics – Novel gene therapy approaches for cardiac diseases.
https://neocor.fr/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 SATT Sud-Est Research, National and local authorities, Research Services | SATT Sud-Est Research, National and local authorities, Research Services | Other 10 Jul 2024 | | |